McKesson Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

McKesson consensus stays solid, analysts see upside for shares - Ad-hoc-news.de

AI-generated analysis

πŸ“ˆ Analysts maintain a 'Moderate Buy' consensus for McKesson with an average price target of $960.53, implying roughly 29% upside from the current trading level.

πŸ“‰ The stock recently opened at $745.12, trading below its 50-day moving average ($785.38) and 200-day moving average ($841.72), indicating a period of consolidation.

🏦 Deutsche Bank reiterated a buy rating with a price objective of $875, supporting the broader moderate buy stance despite being below the consensus target.

πŸ“‰ Institutional ownership saw significant changes as Generate Investment Management reduced its stake by 85.7% in the first quarter according to recent SEC filings.

πŸ’Ό McKesson operates with a substantial market capitalization and remains relevant for major US benchmarks, though it is not part of the S&P 500 healthcare distributors sub-index.

πŸ”¬ The company recently announced a strategic minority interest investment with Apollo funds specifically targeting its Medical-Surgical Solutions unit.

πŸ₯ McKesson's revenue model relies on distributing branded and generic pharmaceuticals, medical-surgical supplies, and providing technology solutions for pharmacies and hospitals.

πŸ“Š The stock's 52-week range spans from $637 to $999, with the consensus target positioned close to the historical high end of this band.

Bullish Signals
  • Analysts maintain a 'Moderate Buy' rating with an average price target of $960.53, representing approximately 29% upside potential from the recent opening price.
  • Deutsche Bank has reiterated a buy rating with a specific price objective of $875, providing support for the stock's valuation despite being below the broader consensus.
  • McKesson recently secured a strategic minority interest investment from Apollo funds in its Medical-Surgical Solutions unit, highlighting strong confidence in this high-growth segment.
Risk Factors
  • Generate Investment Management significantly reduced its stake by 85.7% in the first quarter, indicating a notable shift in institutional positioning for some major funds.
  • The stock is currently trading below both its 50-day and 200-day moving averages, suggesting it is in a consolidation phase below longer-term trend levels.
Full Analysis
McKesson Corporation (NYSE: MCK) maintains a constructive analyst consensus ahead of its upcoming earnings season, with the majority of large Wall Street firms holding a 'Moderate Buy' rating. Data compiled by MarketBeat indicates an average price target of $960.53, suggesting approximately 29% upside from the stock's recent opening price of $745.12 on June 23, 2026. This target is anchored near the upper end of the stock's 52-week trading range, which spans from a low of $637 to a high of $999. Technical indicators show the shares are currently in a consolidation phase, trading below both its 50-day moving average ($785.38) and its 200-day moving average ($841.72). While Deutsche Bank recently reiterated a buy rating with a specific objective of $875, institutional positioning has seen notable shifts, including Generate Investment Management reducing its stake by 85.7% in the first quarter. Fundamentally, McKesson continues to generate revenue through the distribution of pharmaceuticals and medical supplies across North America and Europe, alongside technology solutions for healthcare providers. The company recently highlighted a strategic minority investment with Apollo funds in its Medical-Surgical Solutions unit, reinforcing the importance of this segment which covers essential items like syringes and operating room supplies.